NCT00078520View on ClinicalTrials.gov

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
LeukemiaLeukemia, B-Cell, Chronic
Interventions
BIOLOGICAL

Dose Level 1

IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 0

BIOLOGICAL

Dose Level 2

IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^6

BIOLOGICAL

Dose Level 2- Fixed Dose

IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^7

Trial Locations (1)

77030

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00078520 - Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells | Biotech Hunter | Biotech Hunter